Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan

Naoko Chiba, Miyuki Morozumi, Michi Shouji, Takeaki Wajima, Satoshi Iwata, Keisuke Sunakawa, Kimiko Ubukata

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In Japan, the heptavalent pneumococcal conjugate vaccine (PCV7) has been introduced on a voluntary basis since February 2010, and official financial support for children under 5 years started in November 2010. The impact of PCV7 on invasive pneumococcal diseases (IPD) in children is unknown. There are 340 medical institutions that actively participated in our surveillance project throughout Japan. We collected 252 strains from patients with IPD in 2006 (pre-PCV7), 280 strains in 2010 (under 10% immunization achieved), and 128 strains in 2011 (50% to 60% immunization). Serotypes and penicillin-resistance genotypes (g) were compared between these years. Multilocus sequence typing was also carried out on these strains. Due to the official promotion, IPD significantly decreased in 2011 (p<0.001). In particular, meningitis and sepsis caused by vaccine type (VT) strains declined (p=0.033, p<0.001). In less than 2 years, among nonvaccine types (NVT), 15A and 22F increased in 2011 (p=0.015, p=0.015). Coverage by PCV7 decreased from 71.8% in 2006 to 51.6% in 2011. Sequence-type diversities accompanied by evolution to gPRSP occurred in both VT and NVT strains. Reduction of IPD caused by VT strains was accomplished, but a rapid increase of NVT raises concern about a future decrease in the efficacy of PCV7.

Original languageEnglish
Pages (from-to)308-315
Number of pages8
JournalMicrobial Drug Resistance
Volume19
Issue number4
DOIs
Publication statusPublished - 2013 Aug 1
Externally publishedYes

Fingerprint

Conjugate Vaccines
Japan
Pediatrics
Vaccines
Immunization
Penicillin Resistance
Multilocus Sequence Typing
Financial Support
Meningitis
Sepsis
Genotype

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology
  • Immunology
  • Microbiology

Cite this

Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan. / Chiba, Naoko; Morozumi, Miyuki; Shouji, Michi; Wajima, Takeaki; Iwata, Satoshi; Sunakawa, Keisuke; Ubukata, Kimiko.

In: Microbial Drug Resistance, Vol. 19, No. 4, 01.08.2013, p. 308-315.

Research output: Contribution to journalArticle

Chiba, N, Morozumi, M, Shouji, M, Wajima, T, Iwata, S, Sunakawa, K & Ubukata, K 2013, 'Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan', Microbial Drug Resistance, vol. 19, no. 4, pp. 308-315. https://doi.org/10.1089/mdr.2012.0180
Chiba, Naoko ; Morozumi, Miyuki ; Shouji, Michi ; Wajima, Takeaki ; Iwata, Satoshi ; Sunakawa, Keisuke ; Ubukata, Kimiko. / Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan. In: Microbial Drug Resistance. 2013 ; Vol. 19, No. 4. pp. 308-315.
@article{0e48425821034e269d94544184ce87c8,
title = "Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan",
abstract = "In Japan, the heptavalent pneumococcal conjugate vaccine (PCV7) has been introduced on a voluntary basis since February 2010, and official financial support for children under 5 years started in November 2010. The impact of PCV7 on invasive pneumococcal diseases (IPD) in children is unknown. There are 340 medical institutions that actively participated in our surveillance project throughout Japan. We collected 252 strains from patients with IPD in 2006 (pre-PCV7), 280 strains in 2010 (under 10{\%} immunization achieved), and 128 strains in 2011 (50{\%} to 60{\%} immunization). Serotypes and penicillin-resistance genotypes (g) were compared between these years. Multilocus sequence typing was also carried out on these strains. Due to the official promotion, IPD significantly decreased in 2011 (p<0.001). In particular, meningitis and sepsis caused by vaccine type (VT) strains declined (p=0.033, p<0.001). In less than 2 years, among nonvaccine types (NVT), 15A and 22F increased in 2011 (p=0.015, p=0.015). Coverage by PCV7 decreased from 71.8{\%} in 2006 to 51.6{\%} in 2011. Sequence-type diversities accompanied by evolution to gPRSP occurred in both VT and NVT strains. Reduction of IPD caused by VT strains was accomplished, but a rapid increase of NVT raises concern about a future decrease in the efficacy of PCV7.",
author = "Naoko Chiba and Miyuki Morozumi and Michi Shouji and Takeaki Wajima and Satoshi Iwata and Keisuke Sunakawa and Kimiko Ubukata",
year = "2013",
month = "8",
day = "1",
doi = "10.1089/mdr.2012.0180",
language = "English",
volume = "19",
pages = "308--315",
journal = "Microbial Drug Resistance",
issn = "1076-6294",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Rapid decrease of 7-valent conjugate vaccine coverage for invasive pneumococcal diseases in pediatric patients in Japan

AU - Chiba, Naoko

AU - Morozumi, Miyuki

AU - Shouji, Michi

AU - Wajima, Takeaki

AU - Iwata, Satoshi

AU - Sunakawa, Keisuke

AU - Ubukata, Kimiko

PY - 2013/8/1

Y1 - 2013/8/1

N2 - In Japan, the heptavalent pneumococcal conjugate vaccine (PCV7) has been introduced on a voluntary basis since February 2010, and official financial support for children under 5 years started in November 2010. The impact of PCV7 on invasive pneumococcal diseases (IPD) in children is unknown. There are 340 medical institutions that actively participated in our surveillance project throughout Japan. We collected 252 strains from patients with IPD in 2006 (pre-PCV7), 280 strains in 2010 (under 10% immunization achieved), and 128 strains in 2011 (50% to 60% immunization). Serotypes and penicillin-resistance genotypes (g) were compared between these years. Multilocus sequence typing was also carried out on these strains. Due to the official promotion, IPD significantly decreased in 2011 (p<0.001). In particular, meningitis and sepsis caused by vaccine type (VT) strains declined (p=0.033, p<0.001). In less than 2 years, among nonvaccine types (NVT), 15A and 22F increased in 2011 (p=0.015, p=0.015). Coverage by PCV7 decreased from 71.8% in 2006 to 51.6% in 2011. Sequence-type diversities accompanied by evolution to gPRSP occurred in both VT and NVT strains. Reduction of IPD caused by VT strains was accomplished, but a rapid increase of NVT raises concern about a future decrease in the efficacy of PCV7.

AB - In Japan, the heptavalent pneumococcal conjugate vaccine (PCV7) has been introduced on a voluntary basis since February 2010, and official financial support for children under 5 years started in November 2010. The impact of PCV7 on invasive pneumococcal diseases (IPD) in children is unknown. There are 340 medical institutions that actively participated in our surveillance project throughout Japan. We collected 252 strains from patients with IPD in 2006 (pre-PCV7), 280 strains in 2010 (under 10% immunization achieved), and 128 strains in 2011 (50% to 60% immunization). Serotypes and penicillin-resistance genotypes (g) were compared between these years. Multilocus sequence typing was also carried out on these strains. Due to the official promotion, IPD significantly decreased in 2011 (p<0.001). In particular, meningitis and sepsis caused by vaccine type (VT) strains declined (p=0.033, p<0.001). In less than 2 years, among nonvaccine types (NVT), 15A and 22F increased in 2011 (p=0.015, p=0.015). Coverage by PCV7 decreased from 71.8% in 2006 to 51.6% in 2011. Sequence-type diversities accompanied by evolution to gPRSP occurred in both VT and NVT strains. Reduction of IPD caused by VT strains was accomplished, but a rapid increase of NVT raises concern about a future decrease in the efficacy of PCV7.

UR - http://www.scopus.com/inward/record.url?scp=84880860044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880860044&partnerID=8YFLogxK

U2 - 10.1089/mdr.2012.0180

DO - 10.1089/mdr.2012.0180

M3 - Article

C2 - 23480525

AN - SCOPUS:84880860044

VL - 19

SP - 308

EP - 315

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

SN - 1076-6294

IS - 4

ER -